Stockreport

BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers

BIOSTEM TECHNOLOGIES NEW  (BSEM) 
PDF Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage and market growth The s [Read more]